Diseases that have traditionally been treated in different fields may share a common biological origin. According to Dietmar ...

LB2501 is an off-the-shelf in vivo CAR-T therapy designed to generate dual-targeting CD19/CD20 CAR-T cells directly within ...

BI-1808 monotherapy demonstrated an excellent safety profile and evidence of single-agent anti-tumor activity, correlating ...

Oncolytics Biotech® Inc. has announced the successful completion of enrollment in its GOBLET Phase 1/2 study, alongside the ...

Infiltrating Lymphocyte (TIL) Therapies - Market Size, Target Population, Competitive Landscape & Market Forecast - 2036" has been added to ResearchAndMarkets.com's offering. The report provides a ...

CD122 inhibitor met its primary endpoint in a 126-patient study, demonstrating protection against gluten-induced intestinal damage and supporting advancement into late-stage clinical development. Key ...

First Phase 2 evidence that blocking CD122 can prevent gluten -induced intestinal damage in people living with celiac disease ...

IntroductionThe treatment of malignant lymphoma has always been centered on anticancer drugs. However, treatment strategies, especially for B-cell lymphoma, have changed significantly over the last 10 ...

Clinically meaningful efficacy data observed on primary and key secondary endpoints at Week 36 -- -- Robust durability, including maintenance and ...

ALS (amyotrophic lateral sclerosis) is a progressive neurological disease in which the nerve cells that control movement (motor neurons) are gradually damaged, leading to a decline in muscle strength ...

IMUNON, Inc. announced that the (IDMC) overseeing its ongoing Phase 2 minimal residual disease (MRD) translational study of IMNN-001 has revi ...